The in vitro antimicrobial potency of 10-aza-9-deoxo-l 1-deoxyerythromycin A, the first member of a newclass of macrolide antibiotic, was determined. Several other membersof this family of azalide were prepared and similarly screened in order to begin to define the antibiotic potential of the class. The results indicate that the SARfor this structural type parallels that of other macrolides and that it offers no apparent benefit over known15-membered azalides.
Erythromycin A (1) is one of the great survivors in the antibiotic panoply. While it is unlikely to be wholly supplanted in the near future, new semi-synthetic derivatives have emerged recently as somewhat improved versions and have served to rejuvenate the whole area of macrolide research. One of these newcomers, azithromycin (2)1~3)-the prototypical azalide3)-is of particular interest in that it displays significant potency against Gram-negative pathogens that has not, as yet, been matched by any other macrolide.4) Werecently disclosed the preparation of a new class ofmacrolide antibiotic, the 14-membered azalides, exemplified by the parent structure (3).5) These agents are a conceptual amalgamof the old (1) and the new (2) . Wenowwish to report the in vitro antibacterial profile of a number of representative members of the class.
Chemistry
The preparation of 10-7V-methyl azalide (3) and lactam (4) has been described.5) These materials provided our first glimpse of the antimicrobial potential of this class of macrolide. Nonetheless, given that these compoundspresent a new molecular format for the macrolides it was important to determine whether the established structure-activity relationships for the erythromycins and azithromycin extended to this aglycone. A numberof representative derivatives were selected with this in mind. For the most part the chemistry employed reflects existing macrolide technology and need not be discussed in detail. The starting point in many cases was the 3'-TV-protected synthetic intermediate (6) .5) lO-N-Substitution was probed by preparation of the cyanoethyl derivative (9)3) (i. acrylonitrile (6 to 8), ii. 6% Na/Hg, iii. NOV. 1992 Scheme 1.
HCHO-HCO2H(8 to 9)), the aminopropyl derivative (10)3) (NaBH4-CoCl2 (9 to 10)) and the acetyl derivative (12) (i. Ac2O-py (6 to ll), ii. 6% Na/Hg, iii. HCHO-HCO2H(ll to 12)), together with the unsubstituted, secondary amine (7) (AcOH-THF-H2O-ethanolamine (55) to 7)). Variation at the 4"-position was confined to preparation of the primary amine (13) (Scheme 2), a substitution that has been employed in a number of aglycone systems and generally has a pronounced effect on the in vitro performance. 3'6' 7) Modifications at other sites of the macrolides/azalides have been less frequently addressed and would consequently be of little value for our current purpose. Microbiological Activity Preliminary in vitro antimicrobial screening relied on a standard broth microdilution assay for the determination of MIC's. The results are presented in Table 1 . The control data (1/2) reflects the established erythromycin A/azithromycin relationship3*; the 1 5-membered azalide carries a slight handicap with regard to the Gram-positive organisms1 (although this may not be clinically significant) but reveals its in vitro strengths against the Gram-negative strains. The 14-membered azalide (3) shows a similar pattern of activity. However the increase in MIC's against the Gram-positive organisms is fractionally more pronounced and the decrease in MIC's against the Gram-negative strains less pronounced.* The These differences are consistent and are maintained across an expanded panel of organisms. NOV. 1992 lO-N-substitution group (compounds 3, 7, 9, 10, 12) shows variations in activity that are essentially coherent with the SARin the 15-membered azalide series.
3) The TV-methyl substitution, as for azithromycin, appears to be appropriate but it is important to note that we cannot claim to have determined the "optimal" substitution from such a limited study. The 4"-amino derivative (13) displays the in vitro improvements characteristic of this modification-that is decreased MIC's against the majority of Gram-negative organisms while the Gram-positive profile is barely perturbed. Lactam (4) is inactive.
Discussion
The SARfor this nucleus clearly correlates with the established macrolide pattern. As a working platform, the framework is inferior to the 15-membered azalides. One might predict that the in vivo performance of 3 would emphasize its improvementover erythromycin as a consequence of greater acid stability8) and changes in pharmacokinetic parameters. However one could not expect advances on azithromycin since both materials would likely display analogous in vivo behavior.9) It is difficult to draw any definitive conclusions from this data concerning the role of the aglycone amine. The general conception of the amine is that by increasing the overall hydrophilicity of the macrolide it influences bacterial membranepenetration. That these new azalides showa similar pattern of activity even though the amine is positionally altered maysupport this view of a quiescent, non-specific role. The drop in potency observed for 3 compared to azithromycin may be associated with the lack of the peripheral hydroxy residue at the ll-position. Wehave reason to believe that the ll-hydroxy group is not a "major" determinant of bioactivity for the azalides (A. B. Jones and C. M. Herbert, unpublished results) but may play a role commensuratewith the observed disparity. Nonetheless we cannot rule out the possibility that the presence of the amine, or subtle conformational changes associated with ring size, makea more specific contribution at the level of ribosomal binding and that the 1 5-membered format is intrinsically preferable in this regard.
The catastrophic loss of activity in the case of lactam (4) cannot be reconciled with a simple change in hydrophilicity but more likely reflects a significant conformational change that totally abrogates ribosomal binding. This is underscored by the far less dramatic drop off observed for the acetyl derivative (12).
Experimental

General
Infrared spectra were recorded on a Perkin Elmer 1420 spectrophotometer. *H NMRwere recorded on a Varian XL-400 spectrometer. Mass spectra were recorded on a MAT-731or JOELHX-110mass spectrometer. Microanalyses were performed by Robertson Laboratories, Inc. Erythromycin A was obtained from Aldrich Chemical Co., Inc. All reaction solvents were anhydrous and were obtained from Aldrich Chemical Co., Inc. except for THF which was dried by distillation under nitrogen from sodium benzophenone ketyl. All reactions were performed under dry nitrogen unless otherwise stated.
Chromatography was performed on EMScience Silica Gel 60 (230~400 mesh ASTM) or Fisher Scientific Sorbosil C60 40/60H. Thin layer chromatography was performed on Merck Silica Gel 60/Kieselguhr F-254.
1 0-Aza-1 0-demethyl-9-deoxo-l l -deoxyerythromycin A (7) 1 0-Aza-1 0-(2-cyanoethyl)-1 0-demethyl-9-deoxol 1 -deoxyerythromycin A (9) Azalide (6) (50mg, 61 /rniol) was dissolved in acrylonitrile (0.7ml, 0.09n) and heated to 60°C. After 12hours (TLC CH2C12-MeOH-NH4OH 95 : 5 : 1) the mixture was cooled to room temperature and concentrated. The residue was chromatographed (CH2C12 -MeOH95 : 5) to give the cyanoethyl derivative (8) (48 mg, 90%) as a glass. Lyophilization from benzene gave a white powder. This material was dissolved in THF-MeOH1 : 1 (1.0ml, 0.06n) and potassium dihydrogen phosphate (263mg, 35equiv) added. The mixture was cooled to -20°C and freshly ground 6% sodium amalgam (529mg, 25 equiv) added. After 30 minutes a further 35 equiv of potassium dihydrogen phosphate and 25 equiv of sodium amalgamwere added. After a further 30 minutes (TLC CH2C12-MeOH-NH4OH95 : 5 : 1) the mixture was decanted into aqueous potassium carbonate solution. The amalgamresidue was washedseveral times with ethyl acetate and decanted each time into the aqueous mixture. The aqueous was extracted with ethyl acetate and the combined organic extracts dried over magnesium sulfate, filtered and concentrated. The residue was dissolved in chloroform (1.0ml, 0.09n) and formaldehyde (9/d of 37% aq solution, 2.0equiv) added, followed by formic acid (2/xl, 1.0equiv).
The mixture was heated to 60°C. Cyanoethyl azalide (9) (15mg, 20.2/miol) was dissolved in methanol (1.0ml, 0.02n) and cobalt (II) chloride (9.6mg, 2.0equiv) added. The mixture was cooled to 0°C and sodium borohydride (7.6mg, 10.0 equiv) added portionwise. After 30minutes (TLC CH2C12-MeOH-NH4OH 95 : 5 : 1) the mixture was filtered through Celite, eluting with ethyl acetate. The filtrate was diluted with aqueous potassium carbonate solution and partitioned. The aqueous was re-extracted with ethyl acetate and the combined organic extracts dried over magnesiumsulfate, filtered and concentrated. The residue was chromatographed (CH2Cl2-MeOH-NH4OH 90: 10: 1) to give the aminopropyl derivative (10) (5.5mg, 36%) as a white foam. Lyophilization from benzene gave a white powder. 1 0-Acetyl-1 0-aza-1 0-demethyl-9-deoxo-1 1 -deoxyerythromycin A (12) Azalide (6) (40.0 mg, 49 /imol) was dissolved in pyridine (0.5 ml, 0. 1 n) at room temperature and acetic MIC's were determined by a liquid turbidimetric microtiter assay. Macrolides were solubilized in ethanol and diluted to 4% ethanol in phosphate buffer. Concentrations in the range 128~0.00015 /xg/ml were tested. Stock cultures were stored at -80°C. Organisms were incubated at 35~37°C; Haemophilus influenzae and Streptococcus pneumoniae were incubated in a 5%CO2atmosphere. 105 cfu/well were added to microtiter plates containing the diluted macrolides. Plates were incubated at 35~37°C for 22~24 hours. MICvalues of >8jug/ml indicate microorganism resistance, whereas values of 1^4/ig/ml indicate intermediate resistance. Mueller-Hinton broth was used for all strains with the following exceptions: Haemophilus were grown in Haemophilus Test Mediumand streptococci and enterococci were grown in Mueller-Hinton broth supplemented with cations and 5% lysed horse blood.
